<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13985">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349921</url>
  </required_header>
  <id_info>
    <org_study_id>P01NS041386_TRIAL1</org_study_id>
    <secondary_id>P01NS041386</secondary_id>
    <nct_id>NCT00349921</nct_id>
  </id_info>
  <brief_title>Clonidine Versus Adenosine to Treat Neuropathic Pain</brief_title>
  <official_title>Clonidine Versus Adenosine to Treat Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest School of Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of clonidine and adenosine on nerve
      pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is part of a pain center grant that focuses on how pain, especially chronic
      neuropathic pain, alters the response to traditional and non-traditional analgesics (pain
      medications).

      Clonidine—a drug commonly used to treat high blood pressure—has been shown to effectively
      treat neuropathic pain, is FDA-approved for administration via epidural (an injection given
      in the lower back), and is the third most commonly prescribed drug for chronic intrathecal
      (an injection into the cerebrospinal fluid) use in people with chronic pain.

      Adenosine—a drug commonly administered intravenously (into a vein) to treat certain types of
      abnormal heart rhythms—has been found to reduce areas of allodynia (pain caused by a
      stimulus that does not normally cause pain) after intrathecal, but not intravenous
      administration in people with neuropathic pain.

      Intrathecal clonidine relieves pain by actions on a2-adrenoceptors in the spinal cord,
      whereas adenosine relieves pain by actions on A1 adenosine receptors. Researchers believe
      that intrathecal adenosine and clonidine may prove to be excellent painkillers for nerve
      pain. Therefore, the goal of this study is to determine the effects of clonidine and
      adenosine on nerve pain.

      After initial screening, baseline measurements, and training to learn to estimate pain
      accurately using thermal heat testing, a sample of spinal fluid will be taken from each
      participant. Participants then will be randomly chosen to receive either clonidine,
      adenosine, or placebo. After receiving the study medication, participants will be monitored,
      with their vital signs checked at 30, 60, 120, 180, and 240 minutes.

      Duration of the study for participants is 2 weeks, and includes two visits to the research
      center, each lasting approximately 6 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number Meeting Success Criterion</measure>
    <time_frame>baseline and 2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Verbal pain report 2 hours post injection compared to baseline verbal pain scores prior to injection</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>clonidine first, then adenosine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clonidine given in first injection adenosine given in second injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adenosine first, then clonidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adenosine given in first injection clonidine given in second injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clonidine given first, then placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adenosine given first, then placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clonidine</intervention_name>
    <description>Clonidine—a drug commonly used to treat high blood pressure—has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.</description>
    <arm_group_label>clonidine first, then adenosine</arm_group_label>
    <other_name>duraclon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adenosine</intervention_name>
    <description>Adenosine—a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms—has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.</description>
    <arm_group_label>adenosine first, then clonidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>inactive substance</description>
    <arm_group_label>clonidine given first, then placebo</arm_group_label>
    <other_name>dummy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>inactive substance</description>
    <arm_group_label>adenosine given first, then placebo</arm_group_label>
    <other_name>dummy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with complex regional pain syndrome (CRPS), type I involving a lower
             extremity

        Exclusion Criteria:

          -  Pregnancy

          -  Allergy to clonidine

          -  Currently taking clonidine or other direct a2-adrenergic agonists, or taking
             cholinesterase inhibitors

          -  Patients with any serious or unstable medical problems (heart, lung, liver, kidney,
             or nervous system disease)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C. Eisenach, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Rauck, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Center for Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Center for Clinical Research, 145 Kimel Park Drive</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine, Medical Center Boulevard</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 8, 2014</lastchanged_date>
  <firstreceived_date>July 5, 2006</firstreceived_date>
  <firstreceived_results_date>May 12, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wake Forest School of Medicine</investigator_affiliation>
    <investigator_full_name>James C. Eisenach, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>chronic pain</keyword>
  <keyword>clonidine</keyword>
  <keyword>adenosine</keyword>
  <keyword>complex regional pain syndrome</keyword>
  <keyword>CRPS</keyword>
  <keyword>a2-adrenergic agonists</keyword>
  <keyword>alpha2-adrenergic agonists</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Adrenergic Agonists</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>24 Subjects with chronic pain were recruited from the Center for Clinical Research. Each subject was scheduled for a study visit and randomized to receive spinal clonidine, spinal adenosine or placebo. The subject was scheduled for a second study visit and received the opposite treatment from the first visit.</recruitment_details>
      <pre_assignment_details>24 subjects consented and enrolled 2 subjects withdrawn prior to group assignment because they did not meet inclusion / exclusion criteria on second review</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Clonidine First, Then Adenosine</title>
          <description>Clonidine given during the first period and adenosine given during the second period</description>
        </group>
        <group group_id="P2">
          <title>Adenosine First, Then Clonidine</title>
          <description>Adenosine given during the first period and adenosine given during the second</description>
        </group>
        <group group_id="P3">
          <title>Clonidine First, Then Placebo</title>
          <description>Clonidine given as during the first period, then placebo during the second</description>
        </group>
        <group group_id="P4">
          <title>Adenosine First, Then Placebo</title>
          <description>Adenosine given during the first period and placebo given during the second</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Spinal Injection</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Spinal Injection</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9">One patient experienced an adverse event after period one and did not participate in period two</participants>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clonidine First, Then Adenosine</title>
          <description>clonidine given in first injection adenosine given in second injection</description>
        </group>
        <group group_id="B2">
          <title>Adenosine Given First, Then Clonidine</title>
          <description>adenosine given in first injection clonidine given in second injection</description>
        </group>
        <group group_id="B3">
          <title>Clonidine Given First, Then Placebo</title>
          <description>clonidine given first placebo given in second injection</description>
        </group>
        <group group_id="B4">
          <title>Adenosine First, Then Placebo</title>
          <description>adenosine given in first injection placebo given in second injection</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="1"/>
                <measurement group_id="B5" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="1"/>
                <measurement group_id="B5" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45.2" spread="6.4"/>
                <measurement group_id="B2" value="43.7" spread="10.8"/>
                <measurement group_id="B3" value="19" spread="0"/>
                <measurement group_id="B4" value="54" spread="0"/>
                <measurement group_id="B5" value="43.7" spread="10.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="1"/>
                <measurement group_id="B5" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="1"/>
                <measurement group_id="B5" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number Meeting Success Criterion</title>
        <description>Verbal pain report 2 hours post injection compared to baseline verbal pain scores prior to injection</description>
        <time_frame>baseline and 2 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>The primary outcome measure will be % change in pain report 2 hr following injection, using a response criterion of 30% reduction in ongoing pain.</population>
        <group_list>
          <group group_id="O1">
            <title>Clonidine</title>
            <description>clonidine received as either first or second injection</description>
          </group>
          <group group_id="O2">
            <title>Adenosine</title>
            <description>Adenosine received as either first or second injection</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo received as either first or second injection</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number Meeting Success Criterion</title>
            <description>Verbal pain report 2 hours post injection compared to baseline verbal pain scores prior to injection</description>
            <units>participants meeting success criterion</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that there is no difference between the groups in proportion of patients meeting the success criterion of &gt;30% reduction in visual analog scale pain 120 min after intrathecal injection</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&gt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Clonidine First, Then Adenosine</title>
          <description>clonidine given in first injection adenosine given in second injection</description>
        </group>
        <group group_id="E2">
          <title>Adenosine First, Then Clonidine</title>
          <description>adenosine given in first injection clonidine given in second injection</description>
        </group>
        <group group_id="E3">
          <title>Clonidine First, Then Placebo</title>
          <description>clonidine given first placebo given in second injection</description>
        </group>
        <group group_id="E4">
          <title>Adenosine First, Then Placebo</title>
          <description>adenosine given in first injection placebo given in second injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Regina Curry, RN, CCRC</name_or_title>
      <organization>Wake Forest University Health Sciences</organization>
      <phone>(336) 716-4294</phone>
      <email>recurry@wfubmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
